AngioDynamics, Inc. — Form 10-Q Summary
Reporting period: Fiscal 2017 first quarter, the three months ended August 31, 2016; comparative period is the three months ended August 31, 2015. AngioDynamics develops, manufactures, and sells medical devices for vascular access, peripheral vascular disease, oncology, and surgery.
Financial performance
| Metric | Q1 FY2017 | Q1 FY2016 | Change |
|---|---|---|---|
| Net sales | $88.1 million | $83.8 million | +5% |
| Gross profit / margin | $45.0 million / 51.1% | $43.4 million / 51.8% | Profit +4%; margin down 0.7 points |
| Operating income | $3.6 million | $0.2 million | +$3.4 million |
| Net income (loss) | $1.3 million | $(0.8) million | Improved $2.1 million |
| Diluted EPS | $0.04 | $(0.02) | +$0.06 |
| Operating cash flow | $7.4 million | $4.7 million | +$2.7 million |
Research and development expense rose to $6.7 million from $6.1 million. Sales and marketing fell to $19.5 million from $21.2 million. General and administrative expense was $8.2 million versus $7.9 million. Acquisition, restructuring, and other items were $2.4 million, including $1.8 million in litigation expense and $0.3 million in severance. The medical device excise tax was zero versus $1.0 million, following its suspension.
Revenue trends and material changes
- Peripheral Vascular sales grew 9% to $51.4 million, primarily from angiographic products; management also cited opportunities created by a Cook Medical recall.
- Vascular Access sales increased 1% to $25.0 million, with BioFlo Midline and Dialysis strength offset by softness elsewhere.
- Oncology/Surgery sales declined 2% to $11.1 million, as lower RF sales partly offset growth in Microwave and NanoKnife disposables.
- U.S. sales increased 5% to $71.8 million; international sales grew 8% on a constant-currency basis to $15.7 million.
- Management attributed improved operating income to volume growth and continued margin improvements. Gross margin nevertheless declined, reflecting pricing pressure and product mix, partly offset by sales volume and plant productivity.
Cash, debt, and liquidity
At August 31, 2016, cash and cash equivalents were $37.4 million, marketable securities were $1.6 million, and total debt was approximately $118.2 million. Cash increased $5.1 million during the quarter. Operating cash flow was $7.4 million; investing activities used $0.5 million, principally for capital spending; financing activities used $1.8 million, including $2.5 million of debt repayment and $2.1 million of contingent consideration payments.
The company reported $64.0 million of remaining revolving-credit capacity and stated that cash, investments, operating cash generation, and available revolver capacity should meet anticipated capital needs for at least 12 months. It was in compliance with its credit agreement covenants. Acquisition-related contingent consideration had a fair value of $36.6 million, with approximately $38.7 million of expected undiscounted future payments.
Outlook, risks, and unusual items
- No specific revenue, earnings, or margin guidance was provided. Management identified new product development, licensing, and strategic alliances as growth priorities and highlighted BioFlo, AngioVac, NanoKnife, and Acculis microwave products.
- The estimated full-year effective tax rate before discrete items was 55.2%. AngioDynamics maintained a full U.S. valuation allowance on net deferred tax assets; any future release could materially benefit results, but timing and likelihood are uncertain.
- Two DOJ investigations remain unresolved: one concerning LC Beads distribution and another concerning alleged promotion of certain VenaCure EVLT products for uncleared indications. The company said potential losses could be material but could not be reasonably estimated; no liability was accrued.
- Bard patent litigation involving implantable ports continues. The Utah action is stayed pending patent-office proceedings; a separate Delaware case is proceeding. The company had not accrued a loss because probability and amount could not be reasonably estimated.
- AngioDynamics has judgments against biolitec entities, including a $74.9 million judgment, and continues collection efforts; actual recovery is uncertain.
- Two auction-rate securities, valued at approximately $1.6 million, remain illiquid after failed auctions, although issuers were current on interest payments.
- Other disclosed sensitivities include foreign-currency exposure, interest-rate exposure, acquisition earn-out estimates, product development and regulatory outcomes, and competitive and pricing pressures. Management reported effective disclosure controls and no material change in internal control over financial reporting.
Important facts for investors to verify
- Whether Peripheral Vascular growth and the cited recall-related opportunity persist, and whether growth broadens beyond angiographic products.
- Whether gross-margin pressure from pricing and product mix continues, and whether operating-income improvement is sustainable.
- Developments, potential costs, and any eventual accruals related to the DOJ investigations and Bard litigation.
- Cash generation, debt reduction, covenant headroom, and the timing and amount of contingent consideration payments.
- Whether the U.S. deferred-tax valuation allowance changes and how the unusually high effective tax rate affects reported earnings.
- Collection prospects for the biolitec judgments and liquidity or recovery outcomes for the failed-auction securities.